NeoChord is a leading medical technology company focused on advancing beating heart mitral valve repair for patients suffering from mitral valve regurgitation. As a privately held company, their mission is to improve the quality of life for patients by providing innovative solutions for cardiac health. At the forefront of their offerings is the NeoChord Artificial Chordae Delivery System, a groundbreaking product that received CE market clearance in December 2012.

This cutting-edge technology enables precise and minimally invasive mitral valve repair, reducing the need for open-heart surgery. The company boasts a highly experienced and accomplished Board of Directors, including J. Alex Martin and Andrew ElBardissi, M.

D. With a combined wealth of knowledge in the healthcare and medical device industries, they have successfully transformed global businesses and contributed to significant advancements in cardiac care. NeoChord is dedicated to pushing the boundaries of medical technology, providing hope and improved outcomes for patients with mitral valve regurgitation.

By constantly innovating and collaborating with healthcare professionals, NeoChord strives to make a lasting impact in the field of cardiac health